{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:10:06Z","timestamp":1790014206146,"version":"4.0.1"},"reference-count":16,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Objective: To determine if a relationship exists between oral morphine equivalent (OME) requirements to stabilize acute opioid withdrawal symptoms and the initial buprenorphine dose in patients who successfully complete a buprenorphine microinduction, defined as discharge on buprenorphine.Design: Retrospective chart review.Setting: Single-center community teaching hospital in Lancaster, Pennsylvania.Patients and participants: Included adult patients admitted to Penn Medicine Lancaster General Hospital from February 1, 2022, to February 1, 2025, with opioid use disorder, who attempted a buprenorphine microinduction. A microinduction was defined as an initial sublingual buprenorphine dose less than 2 mg or a buccal dose less than 900 mcg. Patients were excluded if they were on buprenorphine prior to admission. Thirty patients met criteria for inclusion.Main outcome measure: To determine if the 24-hour OME received on the day of buprenorphine initiation (stabilizing OME) is predictive of the starting buprenorphine dose among patients who had a successful microinduction.Results: Of the 30 patients, 25 (83.3 percent) successfully completed a microinduction. Among these 25 patients, there was no statistically significant association found between the initial buprenorphine dose and either the stabilizing OME or the self-reported quantity of illicit opioid use. Similarly, microinduction length was not significantly associated with either variable.Conclusions: Findings support an individualized approach to buprenorphine microinductions, as no statistically significant associations were found between the initial buprenorphine dose and stabilizing OME requirements.<\/jats:p>","DOI":"10.5055\/jom.1002","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:53Z","timestamp":1790011613000},"page":"361-367","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine microinductions: Investigating the ideal initial dose based on oral morphine equivalent requirements for stabilizing withdrawal symptoms"],"prefix":"10.5055","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5901-9500","authenticated-orcid":false,"given":"Temple C.","family":"Coldren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-1402","authenticated-orcid":false,"given":"Katlyn C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"105558","unstructured":"Centers for Disease Control and Prevention (CDC): Understanding the opioid overdose epidemic. 2024; 1. Available at https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html. Accessed May 8, 2025."},{"key":"105559","doi-asserted-by":"crossref","unstructured":"Alexander RS, Canver BR, Sue KL, et al.: Xylazine and overdoses: Trends, concerns, and recommendations. Am J Public Health. 2022; 112(8): 1212-1216. DOI: 10.2105\/AJPH.2022.306881.","DOI":"10.2105\/AJPH.2022.306881"},{"key":"105560","doi-asserted-by":"crossref","unstructured":"Johnson J, Pizzicato L, Johnson C, et al.: Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019. Inj Prev. 2021; 27(4): 395-398. DOI: 10.1136\/injuryprev-2020-043968.","DOI":"10.1136\/injuryprev-2020-043968"},{"key":"105561","doi-asserted-by":"crossref","unstructured":"Reed MK, Borne E, Esteves Camacho T, et al.: Recommendations from people who use drugs in Philadelphia, PA about structuring point-of-care drug checking. Harm Reduct J. 2024; 21(1): 26. DOI: 10.1186\/s12954-024-00937-8.","DOI":"10.1186\/s12954-024-00937-8"},{"key":"105562","unstructured":"Center for Forensic Science Research & Education: Drug checking quarterly report: Quarter 1 and quarter 2. 2023. Philadelphia. Available at https:\/\/www.cfsre.org\/images\/content\/reports\/drug_checking\/2023_Q1_and_Q2_Drug_Checking_Quarterly_Report_CFSRE_NPS_Discovery.pdf. Accessed March 31, 2025."},{"key":"105563","doi-asserted-by":"crossref","unstructured":"Cunningham C, Edlund MJ, Fishman M: The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Am Soc Addict Med. 2020; 14(2S): 1-91. DOI: 10.1097\/ADM.0000000000000633.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"105564","doi-asserted-by":"crossref","unstructured":"Greenwald MK, Herring AA, Perrone J, et al.: A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022; 80(6): 509-524. DOI: 10.1016\/j.annemergmed.2022.05.032.","DOI":"10.1016\/j.annemergmed.2022.05.032"},{"key":"105565","doi-asserted-by":"crossref","unstructured":"Spreen LA, Dittmar EN, Quirk KC, et al.: Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Pharmacotherapy. 2022; 42(5): 411-427. DOI: 10.1002\/phar.2676.","DOI":"10.1002\/phar.2676"},{"key":"105566","doi-asserted-by":"crossref","unstructured":"Moe J, O'Sullivan F, Hohl CM, et al.: Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021; 114: 106740. DOI: 10.1016\/j.addbeh.2020.106740.","DOI":"10.1016\/j.addbeh.2020.106740"},{"key":"105567","doi-asserted-by":"crossref","unstructured":"Spadaro A, Sarker A, Hogg-Bremer W, et al.: Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl. Clin Toxicol (Phila). 2022; 60(6): 694-701. DOI: 10.1080\/15563650.2022.2032730.","DOI":"10.1080\/15563650.2022.2032730"},{"key":"105568","doi-asserted-by":"crossref","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, et al.: \u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019; 74: 76-83. DOI: 10.1016\/j.drugpo.2019.09.003.","DOI":"10.1016\/j.drugpo.2019.09.003"},{"key":"105569","doi-asserted-by":"crossref","unstructured":"Varshneya NB, Thakrar AP, Hobelmann JG, et al.: Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2022; 16(4): e265-e268. DOI: 10.1097\/ADM.0000000000000922.","DOI":"10.1097\/ADM.0000000000000922"},{"key":"105570","doi-asserted-by":"crossref","unstructured":"Huhn AS, Hobelmann JG, Oyler GA, et al.: Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020; 214: 108147. DOI: 10.1016\/j.drugalcdep.2020.108147.","DOI":"10.1016\/j.drugalcdep.2020.108147"},{"key":"105571","unstructured":"CAMP Xylazine Best Practices Policy: Penn Medicine Center for Addiction Medicine. Available at https:\/\/penncamp.org\/wpcontent\/uploads\/2023\/05\/CAMP-Xylazine-Best-Practices-1.pdf. Accessed October 29, 2024."},{"key":"105572","doi-asserted-by":"crossref","unstructured":"Powell VD, Rosenberg JM, Yaganti A, et al.: Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: A systematic review. JAMA Netw Open. 2021; 4(9): e2124152. DOI: 10.1001\/jamanetworkopen.2021.24152.","DOI":"10.1001\/jamanetworkopen.2021.24152"},{"key":"105573","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Mankabady B, Rojas-Fernandez C, et al.: Strategies for transfer from methadone to buprenorphine for treatment of opioid use disorders and associated outcomes: A systematic review. J Addict Med. 2022; 16(2): 143-151. DOI: 10.1097\/ADM.0000000000000855.","DOI":"10.1097\/ADM.0000000000000855"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4139\/4416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4139\/4416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:27:01Z","timestamp":1790011621000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/4139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.1002","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}